RODERICK WONG
CIK 1493280 · Chief Executive Officer · last filed 2026-07-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$384.75M
Companies
16
Total Filings
56
Lifetime Open-Market Net
$70.38M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALLURION TECHNOLOGIES, INC. (ALUR) Delisted | 10%+ Owner | 0 | $8.70 | $0 | $0 | 1 | 2026-07-23 |
| RCKT | Director | 18,263,956 | $3.14 | $57.35M | -$32.05M | 11 | 2026-07-06 |
| OBIO | 10%+ Owner | 9,556,063 | $3.86 | $36.89M | -$264 | 4 | 2026-04-29 |
| KLRA | 10%+ Owner | 10,776,820 | $16.74 | $180.40M | $16.00M | 1 | 2026-04-22 |
| RCKTW | Director | 18,218,457 | $0.00 | $60.1K | $0 | 5 | 2025-07-18 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | 10%+ Owner | 5,175,832 | $4.47 | $23.14M | $0 | 1 | 2024-01-16 |
| Orchestra BioMed Holdings, Inc. (HSAQ) Delisted | Chief Executive Officer | 2,808,512 | $13.31 | $37.38M | $28.10M | 2 | 2023-01-26 |
| MIST | 10%+ Owner | 4,315,102 | $1.07 | $4.62M | $374.6K | 6 | 2022-09-09 |
| Renovacor, Inc. (RCOR.WS) Delisted | 10%+ Owner | 3,000,803 | $0.07 | $213.1K | $18.41M | 4 | 2022-01-20 |
| RNA | Director | — | $11.49 | — | $0 | 1 | 2021-06-17 |
| Landos Biopharma, Inc. (LABP) Delisted | Director | 62,500 | $22.93 | $1.43M | $20.00M | 1 | 2021-02-08 |
| DermTech, Inc. (DMTK) Delisted | 10%+ Owner | 2,887,216 | $0.09 | $271.4K | $3.59M | 3 | 2020-08-19 |
| TELA | 10%+ Owner | 1,175,358 | $0.67 | $787.6K | $554.2K | 1 | 2019-12-17 |
| Immunovant, Inc. (HSACW) Delisted | Chief Executive Officer | 902,498 | — | — | $9.27M | 12 | 2019-12-13 |
| STOK | 10%+ Owner | 3,560,682 | $29.39 | $104.65M | $6.13M | 1 | 2019-11-06 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Director | 0 | — | — | $0 | 2 | 2010-09-22 |
Recent Filings · Page 2 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-26 | RCKTW | Grant (A) | — | $0 | EDGAR |
| 2023-05-05 | OBIO | Other (J) | +1,004,266 | $0 | EDGAR |
| 2023-01-30 | OBIO | Grant (A) | +4,620,000 | $0 | EDGAR |
| 2023-01-26 | Orchestra BioMed Holdings, Inc. (HSAQ) Delisted | Buy (P) | +1,808,512 | $18.09M | EDGAR |
| 2022-12-23 | RCKT | Other (J) | — | $0 | EDGAR |
| 2022-10-11 | RCKT | Buy (P) | +2,711,864 | $40.00M | EDGAR |
| 2022-09-09 | MIST | Mixed | — | $0 | EDGAR |
| 2022-07-25 | Orchestra BioMed Holdings, Inc. (HSAQ) Delisted | Buy (P) | +1,000,000 | $10.01M | EDGAR |
| 2022-06-15 | RCKT | Grant (A) | — | $0 | EDGAR |
| 2022-01-20 | Renovacor, Inc. (RCOR.WS) Delisted | Buy (P) | +88,880 | $711.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.